NORML

JUNE 18, 2019

The administration of herbal cannabis is safe and effective in patients diagnosed with fibromyalgia, according to clinical data published this month in the Journal of Clinical Medicine. ” Patients were most likely to report overall reductions in pain and overall improvements in their quality of life following cannabis therapy.

Patients 279

Patients Therapy Data Safety 279

Cannabis Law Report

JULY 27, 2021

His first initiative is co-authoring an original study on epilepsy using survey data gathered from RoC’s innovative Observational Research Registry (ORR). Schlienz and colleagues have published a paper summarizing ORR data from individuals with epilepsy in the medical journal Epilepsy & Behavior. About Realm of Caring.

Data 105

Data Epilepsy Research and Development Clinical Trials 105

NORML

JUNE 19, 2020

The daily use of cannabis by patients with chronic pain conditions is associated with prolonged improvements in pain management and subjects’ overall quality of life, as well as sustained reductions in the use of opioids, according to longitudinal data published in the journal Pain Medicine.

Patients 340

Patients Chronic Pain Treatment Therapy 340

NORML

FEBRUARY 1, 2019

According to data compiled by the US Centers for Disease Control, the drug was attributed to over 11,500 overdose deaths in 2017. They reported that 30 percent of participants discontinued their use of anti-anxiety medications within two-months of initiating cannabis therapy, and that 45 percent did so by six-months.

Patients 235

Patients Chronic Pain Therapy Data 235

Cannabis Law Report

SEPTEMBER 28, 2021

The data will then be analysed to recognise trends in responses. • Participants: The survey is open to all ACT residents over 18 years. • Use of Data and Feedback: The data will be used in my ANIP thesis and possibly for future research. My ANIP host organisation (Johnathan Davis MLA’s office) may also use the data.

Therapy 52

Therapy Medicine Data Collective 52

NORML

MARCH 23, 2020

.” And according to a recent article in Forbes.com, e-mail mass marketers are spamming in-boxes with what purports to be a Fox News article promoting CBD oils and gummies as a novel COVID therapy.

CBD 336

CBD Therapy Treatment Packaging 336

NORML

FEBRUARY 25, 2020

Trauma patients administered oral THC consume fewer opioids than do similarly matched controls, according to clinical trial data published in the journal Trauma Surgery & Acute Care. An abstract of the study, “Matched pilot study examining cannabis-based dronabinol for acute pain following traumatic injury,” is online here.

Clinical Trials 230

Clinical Trials THC Consumption Therapy 230

The Joint Blog

NOVEMBER 4, 2019

The study found that 58% of physicians agree that “medical cannabis was a legitimate medical therapy.” ” However, as noted by NORML, around half of respondents “expressed discomfort in talking to their patients about medical cannabis options, a finding that is also consistent with prior data. A majority (>?50%)

Therapy 42

Therapy Clinical Trials Conditions Patients 42

NORML

JUNE 10, 2020

The agency’s call for comments, initially posted on April 17 at regulations.gov here , states: “Interested persons or organizations are invited to participate by submitting written views, recommendations, and data related to perspectives on and experiences with pain and pain management.

Chronic Pain 241

Chronic Pain Therapy Patients Topical 241

Cannabis Law Report

APRIL 21, 2021

A new tool provides speed to market with novel psychedelic therapies through deeper data analytics.… … Read More.

Therapy 98

Therapy Data 98

Medical Marijuana Program Connection

MARCH 20, 2023

® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the. BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc.® Read More

Pharmaceutical 52

Pharmaceutical Data Therapy Business 52

Cannabis Law Report

DECEMBER 8, 2021

Access to headline, upfront, milestone and royalty data. Specific therapy indication. Access Psychiatry deal headline, upfront, milestone and royalty data. Advanced Cooling Therapy. Trends in Psychiatry dealmaking in the biopharma industry since 2014. Analysis of Psychiatry deal structure. Upfront payment value.

Access 52

Access Data Pharmaceutical Research and Development 52

NORML

DECEMBER 6, 2019

The transdermal application of plant-derived CBD reduces fascial pain in patients with temporomandibular disorders (TMD aka TMJ), according to clinical data published in the Journal of Clinical Medicine. Subjects receiving treatment reported no adverse effects.

Clinical Trials 107

Clinical Trials Patients CBD Therapy 107

Veriheal

JANUARY 16, 2024

While there is currently no cure for cerebral palsy, various interventions such as physical therapy, occupational therapy, speech therapy, medications, and, in some cases, surgery can be performed to manage its symptoms. Treatment plans are customized to each individual’s needs.

Patients 113

Patients CBD Treatment Research and Development 113

Cannabis Law Report

JUNE 23, 2021

Sapphire Medical Clinics presented six abstracts focused on the latest research on cannabinoids based on data from the UK Medical Cannabis Registry during the 31st Annual International Cannabinoid Research Society Symposium on the Cannabinoids (ICRS2021). PROGRAMME.and.ABSTRACTS. Patient-reported outcomes. Peer-reviewed analysis.

Cannabinoids 59

Cannabinoids Data Chronic Pain Sleep 59

Veriheal

NOVEMBER 30, 2021

Always consult a physician before attempting alternative therapies. He conducted the first blinded human research study into the psychoactive effects of salvinorin A in 2011 and published data on MDMA pill testing services in 2017. In 2014, he developed and published the first research on psychedelic treatment of tobacco addiction.

Research and Development 98

Research and Development Therapy Data Treatment 98

Cannabis Law Report

DECEMBER 14, 2021

(“IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. IGC), based in Maryland, engages in developing cannabinoid-based therapies for healthcare applications.

Clinical Trials 52

Clinical Trials Safety Data Patients 52

Medical Marijuana Program Connection

FEBRUARY 28, 2023

® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company developing groundbreaking therapies for the. BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc.® Read More

Pharmaceutical 52

Pharmaceutical Therapy Data Business 52

Cannabis Law Report

JULY 16, 2021

The diversified venture fund said in a statement that it is focused on tackling the growing global mental health crisis by investing in innovative psychedelic-based and adjacent therapies that are poised to shape the future of psychiatry and fields beyond. Wesana Health Holdings Inc. CSE: WESA) (OTC: DBDIF) is buying Psychedelitech Inc.,

Therapy 124

Therapy Data Patients 124

NORML

NOVEMBER 25, 2019

Patients suffering from persistent pain conditions who frequently use cannabis are far less likely to use non-prescription opioids, according to longitudinal data published in the journal PLOS One.

Chronic Pain 274

Chronic Pain Patients Therapy Data 274

Veriheal

FEBRUARY 21, 2023

Despite notable advances in MMJ research over the last decade, scientists have found that some states’ restrictions on qualifying conditions prevent millions of patients from getting the treatments they need—robbing them of potential relief offered by cannabinoid therapies. How Do MMJ Restrictions Affect Patients and Doctors?

Access 98

Access Patients Chronic Pain Conditions 98

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

NORML

DECEMBER 3, 2019

Adult-use retail cannabis access is associated with a decline in the sales of over-the-counter (OTC) sleep aid medications, according to data published in the journal Complimentary Therapies in Medicine.

Sleep 194

Sleep Access Recreational Therapy 194

Cannabis Law Report

DECEMBER 2, 2021

The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021. IGC) engages in the development of cannabinoid-based therapies for healthcare applications. million individuals in the U.S.

Clinical Trials 52

Clinical Trials Data Patients THC 52

Cannabis Law Report

SEPTEMBER 22, 2021

Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Watch how Supera-CBD works. “We

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

StrainConnect

APRIL 23, 2019

Why Terpenes Are Vital To Your Cannabinoid Therapy. Why Terpenes Are Vital To Your Cannabinoid Therapy. Dont modify these 3 pswp__item elements, data is added later on. -->. By Rachael Maddison with Bradley Slaughter • 24 Apr, 2019. An intro to terpenes and how they work in hemp and cannabis. • 24 Apr, 2019.

Terpenes 63

Terpenes Cannabinoids Therapy Hybrid 63

NORML

NOVEMBER 1, 2019

Those suffering from chronic pain report significant improvements in health following the passage of medical cannabis access laws, according to data published in the journal Forum for Health Economics & Policy. Among state-licensed medical cannabis registrants, two out of three report consuming cannabis to mitigate pain conditions.

Access 172

Access Patients Chronic Pain Law 172

Cannabis Law Report

AUGUST 3, 2021

Many mental health disorders have treatment options, but they aren’t nearly as safe and efficacious as conventional pharmaceuticals or therapies. CSE: MXT) (OTCQB: MXTTF) aims to address these problems by pairing biometric interviews with brainwave data to create a proprietary mental health reference database. Medxtractor Corp.

Research and Development 105

Research and Development Data Conditions Therapy 105

Veriheal

OCTOBER 20, 2021

Always consult a physician before attempting psychedelic therapy. Data from a nationally representative sample of participants have been collected since 1975 to understand drug use trends among American young adults, and noteworthy findings are published each fall. Cannabis and magic mushrooms for the win! A Magical Future.

Therapy 98

Therapy Microdosing Decriminalization Consumption 98

TheAnswerPage

JULY 18, 2022

Do patients report more side effects from cannabidiol (CBD)-rich extract therapy or from purified CBD therapy? Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis Front. Pamplona F, da Silva L and Coan A. 12 September 2018.

Epilepsy 52

Epilepsy Therapy Extraction Treatment 52

TheAnswerPage

JULY 19, 2022

Have researchers found that patients who use cannabidiol (CBD)-rich extract therapy for the treatment of epilepsy require a lower dose of CBD medication as compared to those who use purified CBD therapy for the treatment of epilepsy? Pamplona F, da Silva L and Coan A. 12 September 2018. Sec.Neuropharmacology. See the Answer.

Epilepsy 52

Epilepsy Therapy Extraction Data 52

MMJ Recs

NOVEMBER 17, 2023

Promoting Research and Innovation The medical marijuana industry promotes research and innovation in the field of cannabis-based therapies. Research and Innovation: Maryland’s MMJ program encourages research and innovation in the field of cannabis-based therapies, benefiting patients both in the state and nationwide.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Veriheal

DECEMBER 15, 2021

Published in the Journal of Medical Internet Research, the fresh data suggests that the cannabinoids found in cannabis, such as THC and CBD , may have potential as a treatment for sleep deprivation. The post Cannabinoids May Promote a Good Night’s Sleep, Study Finds appeared first on Cannabis Central.

Sleep 98

Sleep Cannabinoids Therapy Treatment 98

The Joint Blog

MARCH 3, 2021

The study found “significant improvements were observed” following the initiation of cannabis therapy in most patients. The study concludes by stating that “The current study revealed the positive effects of MC [medical cannabis] therapy in some patients with FMS [ fibromyalgia syndrome] and resistance to conventional treatment.

Therapy 61

Therapy Hybrid Marijuana Research and Development 61

Veriheal

JUNE 30, 2023

Researchers say this emphasizes just how important it is that psilocybin therapy be done in a controlled setting with therapy and community-based after-care. The 14-page document covers several aspects of the drug development process, including trial best practices, data collection, and new drug application requirements.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

OCTOBER 13, 2021

But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. An abundance of science and public health data supports it. Psilocybin, a compound produced by many species of fungi, is one of the most well-studied psychedelics.

Research and Development 52

Research and Development Therapy Access Data 52

Cannabis Law Report

JANUARY 12, 2022

According to a recent report released by the Psychedelic Science Funders Collaborative, “Oregon’s psilocybin therapy program provides a high-quality model for psychedelic healing in a non-prescription context that could be replicated in other states.” ABOUT THE NATIONAL PSYCHEDELICS ASSOCIATION.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52